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Abstract
Introduction: Delivery of intermittent preventive treatment with sulphadoxine-pyrimethamine to pregnant women (IPTp-
SP) through antenatal clinic (ANC) in Mali is low, and whilst ANC delivery of insecticide treated nets (ITNs) is higher, coverage
is still below national and international targets. The aim of this study was to explain quantitative data from a related study
which identified ineffective processes in the delivery of these interventions in one district in Mali.
Methods: In-depth interviews were conducted with health workers at the national, regional, district and health facility levels
on their perceptions of reasons for the ineffective processes identified in the quantitative study, and their reported
practices. Themes were coded for each ineffective process, and within these a health systems lens was used. Content
analysis was used for emergent themes within this framework. MindMaps were used to display the findings.
Results: Intervention specific factors for the ineffective delivery of IPTp-SP included misunderstanding of the upper limit of
the gestational age at which SP could be given and side effects of SP. Incorrect practices had been recommended in training
and supervision of health workers. Pregnant women who were ill on attendance at ANC were not consistently managed
across health facilities. The most common reason for not offering women an ITN on their first ANC visit was if they were
from outside the health facility catchment area. Broader health systems issues influencing the effectiveness of delivery of
each of these interventions were also identified.
Conclusion: In this setting, intervention-specific factors resulted in the ineffective delivery of IPTp-SP. These relate to
complex policy guidelines, lack of guidance on how to implement the guidelines, and the institutionalising of practices that
undermine the national guidelines. Interventions may be implemented and show real gains in the shorter-term whilst
waiting for broader health systems issues to be addressed.
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Introduction
Intermittent preventive treatment with sulphadoxine-pyrimeth-
amine (IPTp-SP) for pregnant women and insecticide treated nets
(ITNs) are the current recommended preventive approaches in the
fight against malaria in pregnancy [1]. Coverage of both
interventions is well below the current targets of 100% for
IPTp-SP and ITNs [2].
The delivery channel for IPTp-SP is almost exclusively
antenatal clinics (ANC). Although data from the demographic
and health surveys (DHS) would suggest that a varying proportion
of pregnant women across countries of sub-Saharan Africa (SSA)
obtain SP for prevention during pregnancy outside of ANC,
almost nothing is known about the dosages received, and from
where they are received, and whether these may constitute IPTp-
SP. Women should receive IPTp-SP twice during pregnancy with
the first dose in the 4th month of gestation and each dose at least
one month apart [3]. According to the Malian national policy,
IPT-SP should be given twice during pregnancy, free of charge,
and should not be given to women in the ninth month of
pregnancy [4]. ITNs are delivered through a multitude of channels
[5,6], with perhaps the largest proportion of ITNs currently in
households in SSA having been delivered through mass campaigns
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[6]. Nevertheless, countries of SSA also have a policy of delivery of
ITNs through ANC to pregnant women [7], and some countries
have achieved considerable coverage within households through
this channel [8].
In Mali both IPTp-SP and ITNs are delivered through ANC
and whilst 71% of women access ANC at least once, the disparities
in this access across socio-economic groups are very high [9]. The
proportion of pregnant women receiving at least one dose of IPTp-
SP as measured in this same DHS was just 6.0%. Given the
proven continuing effectiveness of IPTp-SP in Mali [10], it is
important to understand the reason for these substantial missed
opportunities, such that interventions can be designed and
implemented to increase the proportion of women receiving this
intervention.
A study was conducted in Segou District to 1) describe the
health systems algorithm for delivery of IPTp-SP and ITNs, 2) to
quantify the effectiveness of each of the intermediate processes in
this algorithm, and 3) to identify predictors of effectiveness of
intermediate process that were found to be ineffective (Webster
et al Unpublished). The health systems algorithm defines each of
the processes that need to occur for pregnant women to be given
effective IPTp-SP, with each of these defined as intermediate
processes. Ineffective intermediate processes were defined as those
that were undergone by less than 80% of pregnant women. The
delivery of IPTp-SP was found to be ineffective in the study
setting. Two intermediate processes were found to be particularly
ineffective which were: a pregnant woman being given any SP
during the ANC visit observed; and being given IPTp-SP by
directly observed therapy (DOT). Methods and results of the
quantitative study are summarised in Box S1.
Here we report on a qualitative study undertaken approxi-
mately 18 months after the quantitative survey that sought to
understand the reasons why these intermediate processes were
found to be ineffective, together with the reasons why some
pregnant woman were not offered an ITN, from the perspective of
the health workers in the study sites. We use a health systems lens
through which to view health worker perspectives of the ineffective
processes in the delivery of both IPTp and ITNs.
Methods
Ethics
The study was approved by the ethics committees of the Faculty
of Medicine, Pharmacy, and Odonto-stomatology, University of
Bamako, the London School of Hygiene and Tropical Medicine,
and the Liverpool School of Tropical Medicine. Health workers
gave signed consent for the in-depth interviews and for the use of
anonymous quotes.
The study was undertaken in Segou District, Segou Region,
Mali. The district has a total of 29 functioning health structures
comprising 1 hospital, 1 district level health facility (Centre de sante´ de
reference), and 27 community health centres (CSComs). At the time
of the study there were 8 non-functional CSComs. The hospital
serves as the regional referral centre and the Centre de Sante´ de
Reference (CSRef) for district level referrals. An overview of the
study setting was presented in the companion paper Webster et al
Unpublished and further details of the health systems context are
presented below.
Sampling and study procedures
Health workers from the national, regional, district and health
facility levels were purposively selected for the study to represent
the views of a range of levels and roles within the health system.
Health facilities included in the study were amongst those selected
for the companion quantitative study. Health facility interviewees
were either managers of the facility or ANC, or were at the
frontline of delivery of ANC and delivery. Interviews were
conducted with the health workers in French and the local
language (Bambara), by one of the authors (SaD). Interview
themes included: pregnant women’s access to ANC, the services
provided within ANC and the structure of these services, and the
examinations and interventions delivered through ANC, including
Figure 1. Factors reducing the effectiveness of receiving any IPTp-SP by pregnant women of eligible gestation during an ANC visit.
Note: SP, sulfadoxine-pyrimethamine; ANC, antenatal clinic; DOT, directly observed treatment; HIV+ve, human immune deficiency virus positive.
doi:10.1371/journal.pone.0065437.g001
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Table 1. Diagnosis categories for ineffective implementation of the delivery of IPTp-SP and ITNs based upon quotes of health
workers.
Receive any SP
Governance: misinterpretation/lack of knowledge of national guidelines
a) Upper limit
‘‘We give [IPTp-SP] to pregnant women from 4 months of pregnancy until 7 months. At the 8th month, it cannot be given.’’ (Health worker 9)
‘‘It is the first trimester and from 8th month that pregnant women must not take SP otherwise they can take it.’’ (Health worker 13)
‘‘If they come at 7 months, their next appointment will be 8 month, we cannot give SP, we can still assess the pregnancy.’’ (Health worker 1)
a) Lower limit
‘‘We provide iron tablets and SP. But if the pregnancy does not reach 1 month we do not provide SP.’’ (Health worker 6)
Governance & Financing: charging for ‘free’ SP
‘‘There was SP for sale each time the free SP finished. This was in controversy to what the policy said. ‘‘(Health worker 4)’’
Governance & Financing: lack of harmonisation
‘‘For the SP, we have encountered difficulties because there are partners who started giving free SP to pregnant women while at the same time, SP was available for sale in the
system. There was no harmonization’’ (Health worker 10)
Financing
‘‘SP is not for sale. However, the country is so big that there are maybe some people who do don’t want to understand. Otherwise, there are directives, circulars, letters sent to
all levels about the provision of free SP. Now the PPM [National Pharmacy of Mali] does not provide SP for sale. If there still exist SP to sell, that means that people decide
themselves, to do it.’’ (Health worker 10)
‘‘But what happen is that because of the free distribution of SP as recommended by the national level, if free SP [from the government] is not available, some health centres
buy SP in another place and cannot provide it free of charge because they paid it from other sources. So there will be a problem for that‘‘ (Health worker 4)
‘‘If free SP is in stock out, we have SP from other sources for sale. This is prescribed to pregnant women to buy. ‘‘ (Health worker 5)
Human resources: cascade training
‘‘The initial training is organized at the national level with the trainers. We train people from the region that also train trainers of district level on IPTp-SP. The districts also
train the matron and the midwives.’’ (Health worker 10)
Products & technologies: SP side effects
‘‘The problem is about adverse event that it creates when taken while stomach is empty. It [SP] can lead to dizziness, and trembles. This makes us worry about problem that
could arrive like unconscious....... Some women have a stomach problem.’’ (Health worker 12)
‘‘A lady has told me that she vomited after she took SP while she had an empty stomach. Another told me that, when she took it she was not able to do anything, even to
work.’’ (Health worker 14)
Products & Technologies: stock-outs
‘‘There is also a problem with the distribution, because there are some regions which even don’t need inputs and they received systematically a big quantity.’’ (Health worker
4)
‘‘The districts started to experience stock out problem with SP. The districts have asked about SP, and we also asked the national level. Maybe the national level also does not
have it...... As I said, we have sent our order, but we did not receive any answer yet...... It was about four months, we have faxed to the NMCP and the PPM, but we did not have
answer yet.’’ (Health worker 4)
Service delivery: give to take at home
‘‘In rural areas it is not easy because most of the women come while stomach is empty and it is not easy to take [SP] right away. That is why the tablets are attached together
in the plastic bag so that they can take it at home after they eat.’’ (Health worker 9)
‘‘Because we had this same problem with iron dose; we told them to take it with a piece of bread or at night when they go to bed. (Health worker 4)
Service delivery: don’t give to take at home
‘‘We ask them to eat, otherwise we do not give them [SP] to bring at home because some don’t take it. .....We often demand them to take after eating, as generally it is the
market days there is selling food in the market; since some women throw them we don’t give them to bring at home.’’ (Health worker 1)
‘‘It seems that a woman delivered last Saturday and there was SP found in her bag. When we asked her why she did not take the SP she said that she forgot....... It is good that
they don’t carry at home otherwise they will not take it.’’ (Health worker 8)
Service delivery: deal with illness first
‘‘We start with illness by prescribing and do normal ANC later...... In case of disease, we give prescription. This does not stop the normal procedure of ANC visit.’’
(Health worker 1)
‘‘There are two possible cases. If they come for ANC visit and we discover that they are sick, we first do the treatment and give another appointment for the ANC visit. If they
come for disease and we discover that they are pregnant, we also treat the disease and ask her to come back for ANC visit.’’ (Health worker 6)
Service delivery: has malaria
‘‘Some do not come for ANC visit, but only when they want malaria treatment. If we found that she suffers from malaria, we give treatment for malaria; and if she recovers we
perform the normal ANC visit. We always treat the disease first before the ANC visit.’’ (Health worker 8)
‘‘Except she has malaria; In that case we cannot give SP, because she is already having malaria treatment. We are no more in prevention but treatment. We give SP during the
next ANC visit.’’ (Health worker 14)
Take SP by DOT
Human resources and products & technologies : training and side effects of SP
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the delivery of IPTp-SP, ITNs and malaria case management and
specifically health workers’ perceptions of factors influencing
delivery of these interventions within ANC. Interview guides were
unstructured and all questions were open ended. The interviews
were flexible, allowing exploration of emergent issues that were
not in the original topic guide but were raised by the interviewees.
Themes were thus developed inductively throughout the study,
with emergent themes in one interview being included in
subsequent interviews.
Coding and analyses
The interviews were transcribed, translated and entered into
NVivo version 8 for data management and analysis. All
translations were verified by one of the authors (KK). After
familiarisation with the data, a framework approach [11] was
taken to the analysis at two levels. The first level was coding of data
around the primary framework themes of: 1) health systems
context; 2) being given any SP during a visit to ANC; 3) being
given IPTp-SP by DOT in ANC; and 4) being offered an ITN.
The secondary framework themes, were those of the six building
blocks of the health system which are: governance; financing;
human resources; health information; products and technologies;
and service delivery [12]. Responses of interviewees within each of
the four primary framework themes listed above were coded for
the six building blocks. Interviewees were not directly asked about
these secondary framework themes. Content analysis was used
within each of the health systems building blocks to identify
emergent issues and to further divide themes into emergent sub-
themes where indicated by the data.
Mind maps were developed using Mindjet MindManager 2012
to provide a visible representation of the emergent issues within
building blocks of the health system for each of the primary
framework themes. All interviewees were assigned anonymous
health worker numbers, so that neither roles, levels within the
healthcare system, nor health facilities identified in order to
preserve anonymity. Quotes supporting emergent themes within
the primary and secondary frameworks were tabulated and used to
support text on the qualitative findings and to triangulate and
explain the quantitative findings in the companion paper. Issues
identified in the analysis of the qualitative data were compared
with respect to predictors of each of the 3 ineffective processes
identified in the quantitative data as presented in the companion
paper (Webster et al Unpublished).
Methods for the quantitative study are presented in the
companion paper. No new analyses of quantitative data were
conducted for this paper, but findings presented previously are
used to strengthen, compare and contrast with the qualitative
findings presented here.
Results
A total of 18 in-depth interviews with health workers were
undertaken, including 1 from the national level, 2 regional level, 5
from district level management or referral health facilities, and 10
from community level health facilities (3 facility heads/deputy
heads, and 7 ANC staff). Interviewees were representatives of the
malaria control programme and of the reproductive health
programme, health facility heads, or staff of ANC. They had
Table 1. Cont.
Take SP by DOT
‘‘The recommendation is to provide SP as a DOT, but there is a small problem that we are solving with midwives during the training. There are people who say that they
cannot take it [SP], because it causes dizziness with an empty stomach. Hence the midwife asks them [pregnant women] to take it at home. But we provide advice to women
to eat before they come to ANC so that they will take it as a DOT. Now it starts to be OK. ‘‘(Health worker 10)
Governance: supervision incorrect guidance
‘‘We give three tablets of SP we put in a plastic bag to take at home after a meal. All the tablets should be taken together. We used to have the DOT approach before, but we
changed to that one [giving to take at home] after a supervision which asked to give to take at home after eating. When taken without eating, it causes shakes, and can
cause dizziness. That is why we don’t give it as DOT...... They [supervisors] said that it is not a good solution to go and find a food to eat and come back again for (Health
worker 6)
Service delivery: give SP to take outside with food
‘‘Sometimes we give them and we ask them to eat. Usually it is the market day they can find food everywhere in the market.’’ (Health worker 15)
‘‘We ask them to buy some food outside and to take the SP, because we are not sure that they will take it at home.’’ (Health worker 14)
Service delivery: give SP to take at home with food
‘‘As some women say that they did not eat, and as we know that it can create bad fatigue when you take it hungry. It can also give vomiting to some women. We then ask to
take it at home after they eat.............’’ (Health worker 14)
‘‘In our AN visit rooms, there is SP and water; we ask them to take it as DOT, but some don’t want to take it because they did not eat before and that it may give vomiting to
them. We then ask them to take at home after they eat.’’ (Health worker 13)
Offer an ITN
Financing and Products & technologies
‘‘We are provided by CSREF according to the size of our population. The CSREF gives us what we ask for. Sometimes we go there and take, and sometimes they bring it here
and we pay their gas for the car that transports it.’’ (Health worker 15)
‘‘For ITNs, there are sometimes difficulties to provide to the districts because of their transportation, also from the district to the CSCOMs. This is a big problem because, the
national level was supposed to provide to the regional level, and from there to the districts and from there to the CSCOMs. There was no budget to support that, and hence
there was stock out problem.’’ (Health worker 10)
Service delivery: rationing
‘‘The ITNs are given only to the woman that lives in the areas covered by the CSCOM. Those coming from outside the CSCOM area do not benefit ITN. I am sorry for that fact
because it is not normal that pregnant wome do not have ITN during AN visit. Before, we give ITNs to all people in and outside the CSCOM areas, but since there is insufficient
ITNs, the decision has been taken to provide ITNs only to those from the CSCOM area.’’ (Health worker 9)
doi:10.1371/journal.pone.0065437.t001
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been in their respective roles for 1 to 25 years. The narrative for
each of the 3 ineffective processes: receive any SP during ANC,
receive IPTp-SP by DOT, and offered an ITN, as presented below
are therefore based upon the perceptions of the interviewees from
discussions during the in-depth interviews and includes their
reported practices.
Context
The characteristics of ANC services in the study facilities and
their distance from the CSRef (Segou town centre) were presented
in the companion quantitative paper (Webster et al Unpublished).
CSCom had ANC twice per week, and conducted outreach via
community health workers known as relais. Supervision from the
Programme National de Lutte Contre le Paludisme (PNLP)
together with the regional level to approximately 4 districts per
region and 2 CSCom per district was conducted on a 6 monthly
basis. It was the responsibility of the malaria and reproductive
health focal points based in the CSRef to supervise the CSComs
on a more frequent basis. The major limitation to the frequency of
supervision was reported as resources for transport. According to
the perceptions of those interviewed there were problems in
communication between programmes and between levels within
programmes. There was no communication between the malaria
and reproductive health focal points at the regional level. The
regional malaria focal point linked with the district level malaria
focal point but the regional reproductive health focal point did not.
There were weak links between the national level and Regional
reproductive health focal points.
Salaries of health workers were reported as being paid from a
variety of sources: the government, community health centre
board (ASACO), mayor, and Pays Pauvres Tres Endettes (PPTE)
funds. Those health workers paid by the government were
generally the more senior staff such as medical doctors. The
community financed CSComs needed to charge money from
patients in order to finance the services they offered. Responses
from interviewees on the generation of money for financing the
facility from ANC included a number of costs to the pregnant
women: an ANC ‘ticket’ on entering the facility, ANC card, ANC
consultation, lab tests, gloves, prescription order and SP. The
number of these cost categories that women needed to pay varied
across CSComs, as did the amount that they paid for each. Fees
were higher for those attending the CSCom from outside the
defined catchment area of the health facility.
Planning for drug supplies was reported as being on an annual
basis; amounts were requested of the Programme National de
Lutte contre le Paludisme (PNLP) by regions and these were
considered in the light of recommendations from a quantification
committee. The orders were then placed by the Pharmacy
Populaire du Mali (PPM). Once the drugs were received by the
PPM and PNLP were informed, it was then the responsibility of
the PNLP to distribute them to the regions. The districts and
CSComs in turn, were then responsible for collecting their supplies
from the region.
Receive any SP during the observed ANC visit amongst
those of eligible gestation
Approximately two thirds of pregnant women (63.9%) who
were of eligible gestation when they attended the CSRef for their
first ANC visit were given SP, whilst three quarters of eligible
pregnant women (74.0%; 95% CI 62.0, 83.3) were given SP on
their 1st visit to the CSCom (Webster et al Unpublished).
Interviewees’ responses on the reasons that pregnant women of
Figure 2. Factors reducing the effectiveness for pregnant women of receiving any IPTp-SP by DOT when of eligible gestation
during an ANC visit. Note: SP, sulfadoxine-pyrimethamine; ANC, antenatal clinic; DOT, directly observed treatment; IPTp, intermittent preventive
treatment.
doi:10.1371/journal.pone.0065437.g002
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eligible gestation may not receive IPTp-SP during an ANC visit
included issues related to all six health systems building blocks
(Figure 1). Each building block was considered in turn and links
between the blocks highlighted in the text below and in supporting
quotes presented in Table 1. Other relevant quotes which were not
necessarily about factors influencing ineffective delivery were
incorporated into the text below.
Governance. According to the national guidelines eligibility
for IPTp-SP amongst pregnant women attending ANC was
dependent upon the gestation of their pregnancy and should be
given between 4 months and 8 months gestation, inclusive; IPTp-
SP should not be given before 4 months or after 8 months [4].
The reported practice from health workers in relation to gestation
and giving IPTp-SP varied. Whilst some health workers
interpreted the guidelines correctly, others showed either misun-
derstanding of, or lack of knowledge of these guidelines. The belief
that IPTp-SP could not be given in the 8th month was a common
perception showing a misinterpretation of the upper limit of the
policy. Where a woman’s second ANC visit was anticipated to
occur in an ineligible month of gestation, that is month 9, in some
cases the first dose would be denied even though the first dose
could be given in an eligible month of gestation. In other cases
Table 2. Factors influencing reduced effectiveness of intermediate processes in the delivery of IPTp-SP, IPTp-SP by DOT and ITNs
(in the presence of required stock).
Quantitative (Adjusted predictors) Diagnosis Category Qualitative explanation
Receive any SP
- Education
(Qprimary+ in CSCom)
Service delivery No direct explanation
- Gestation
(q4 to 6 months;
ref 7-8 in CSRef + CSCom)
Governance: guidelines Misinterpretation of guidelines on gestation when IPTp-SP should be given
particularly the upper limit. Includes don’t give during the 8th month commonly,
and sometimes in the last trimester
- Reason attend
ANC (QANC + ill in CSCom)
Service delivery: illness Illness often dealt with first; woman may not receive routine ANC visit
- Has symptoms of malaria
(Qyes in CSRef)
Service delivery: illness Illness dealt with first; if given treatment for malaria should not be given IPTp-SP on
the same visit. Note this is the correct action but will result in a decreased
effectiveness measure unless such cases are removed from the effectiveness
denominator
- Was palpated
(qyes in CSCom)
Service delivery No direct explanation
- Total money spent
(q500–999; ref ,500 in CSRef)
Governance:
Co-ordination & harmonisation
Financing: subsidy
SP should be free and sometimes was free, but was also sometimes being sold.
Those spending .CFA999 were likely to have been ill and given alternative
treatment
- Spent any money in the health
facility (qyes in CSComs)
Financing: No direct explanation
None Products & technologies;
Service delivery
Side effects of SP when a woman takes on an empty stomach. Due to side effects of
SP when a woman takes on an empty stomach, IPTp-SP is given to be taken at
home, or not given (possibly with the woman directed to return after eating)
SP by DOT
Total money spent
(q. 500 FCFA)
Financing: subsidy No direct explanation
None Governance: supervision Health workers told during supervision not to give ITPp-SP by not because of side
effects but to give to take home and instruct to take with food
Human resources: training Health workers told during training that there are side effects if IPTp-SP given on an
empty stomach and therefore not to give if the woman hasn’t eaten
None Products & technologies;
Service delivery
Side effects of SP when a woman takes it on an empty stomach women therefore
women not given by DOT if they have not eaten before accessing the ANC
Offered an ITN
- SES (Qquintile 4) Service delivery No direct explanation
- woman reports malaria in
consultation (qyes)
Service delivery No direct explanation
- was palpated (qyes) Service delivery No direct explanation
- Pay for consultation (qyes) Financing No direct explanation
- total money spent
(q.1,000 FCFA)
Financing No direct explanation
None Financing; Products & technologies Due to rationing of ITNs, those from outside the catchment area of the CSComs are
not given an ITN
Notes:
SP, Sulfadoxine-pyrimethamine; ITN, Insecticide Treated Net; CSCom, Community health center; CSRef, Reference health center; ANC, Antenatal Clinic; DOT, Direct
Observed Treatment; IPTp, Intermittent Preventive Treatment; SES, Socio-economic Status; CFA, Franc XOF;
q, arrow indicating high level; Q, arrow indicating low level.
doi:10.1371/journal.pone.0065437.t002
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health workers reported that they would deny IPTp-SP to a
pregnant woman of less than one month gestation, rather than 1st
trimester as per the guidelines.
In addition to the months of gestation guideline for when to give
IPTp-SP, ‘quickening’, or movement of the baby should have
occurred before the first dose is given. No misinterpretation of this
guideline was found in the interviews. However, if quickening was
expected by the health worker but not reported by the pregnant
woman, the fundal height was measured.
Only one health worker showed any confusion on advising that
3 tablets per dose of SP should be taken, this health worker was
directly involved in delivery of ANC services. No health worker
interviewed reported anything other than that two doses of IPTp-
SP should be taken (except in HIV positive women who, as per
guidelines should get 3 doses). Reports of information given to
pregnant women on the one month gap required between doses of
IPTp-SP were all correct. There was a general worry that the
interval between doses was often more than one month, but
according to reported practice this did not prevent health workers
from delivering the delayed dose.
‘‘I have heard that women with less weight should take 2 tablets and
later on one tablet.’’ (Health worker 13)
‘‘SP is given with at least one month interval. Sometimes it is not exactly
what we do. If the women come during the 5th month and she receives
the dose of SP we give an appointment for the 6th month. Many women
don’t respect that. In that case she comes during the 7th month to receive
the second dose.’’ (Health worker 9).
According to the national guidelines IPTp-SP should be
delivered to pregnant women within the health system, free of
charge. However, ‘free SP’ was available only when supplied by
UNICEF, and when the UNICEF SP was out of stock, SP was
available for sale. Perceptions of health workers on this varied with
some worried about not complying with the guidelines and others
more worried about harmonisation of financing strategies.
Financing. Linking to guidelines and harmonisation issues
above it was recognised that pregnant women should no longer be
charged for SP but that charging was a consequence of stock-outs
of the government provided SP. Buying SP from other sources
therefore represents a stock-out coping strategy. When free SP is
out of stock at the CSComs, they obtain SP from the CSRef to sell.
Human resources. Human resource issues specific to
delivery of IPTp-SP and ITNs were not mentioned by the
interviewees with the exception of training which was described as
cascade training from the national to regional to district to facility.
The movement of health workers between health facilities where
they had been trained to other health facilities was also viewed as a
problem.
Figure 3. Factors reducing the effectiveness of pregnant women being offered an ITN during their first ANC visit. Note: ITN,
insecticide treated net; ANC, antenatal clinic visit; CSCom, centre de sante´ communautaire, corresponding to community health centre.
doi:10.1371/journal.pone.0065437.g003
Qualitative Health Systems Effectiveness
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e65437
Products and technologies. SP was generally seen as a drug
for prevention of malaria, with good understanding amongst some
health workers of its health impact for both the mother and baby.
SP was seen by some however, as a drug which could not fully
prevent malaria, but reduced the severity of disease once infected.
‘‘SP prevents baby and the mother against malaria, because malaria
during pregnancy is very severe. SP prevent against still birth,
prematurity, haemorrhages. (Health worker 12)
‘‘I think it is a preventive measure; it cannot prevent them to get disease,
but a woman who respect that even if she gets disease it would not be
serious.’’ (Health worker 7).
Factors influencing the delivery of IPTp-SP relating to products
and technologies as discussed by the interviewees were twofold
relating to side effects of SP and to its product and supply chain
management. Side effects of SP as reported by the health workers
were mainly dizziness and vomiting. Dizziness was linked to not
having eaten before taking the tablets and therefore having an
empty stomach. Pregnant women taking SP on an empty stomach
was reported as a problem by the majority of health workers
interviewed.
Interviewees variously reported that in the health facilities stock-
outs were common and for periods of as long as two months, in
other facilities staff reported that they had not experienced stock-
outs of SP. Differing responses on stock outs of SP may be due to
the interpretation of free and non-free SP, that is, the purchasing
of stock from other sources by facilities when government stocks
run out. The stock provided from partners was perceived as having
stabilised stock at the national level.
‘‘The stability about SP stock out is good from 2 years to now because
there is enough SP from UNICEF, USAID’’ (Health worker 10).
However, problems in Product and Supply Chain Management
(PSCM) at the regional, district and health facilities were
described. SP stock was determined based upon population
estimates but was described as inadequately taking into account
malaria transmission which is variable across regions and districts
of Mali. This translates to poor forecasting of needs. Based upon
the interviews communication between the regions and the
national level on supply can be problematic. When there was
stock out at the national level, communication with timelines and
expectations was sub-optimal. Supply of SP from the regions to the
district and on to the health facilities was mentioned in the context
of the wider PSCM systems, rather than specifically in relation to
SP. The main problem was that of financing in terms of the
availability of money for fuel for transport of drugs.
Service delivery. According to the health workers inter-
viewed, the process through which a pregnant woman progressed
on attending ANC varied depending upon whether she attended
for a routine visit only, or because she was ill too. Based upon the
quantitative findings 18 months before these interviews, a high
proportion of women attend for routine ANC and to report an
illness (27.4% CSRef and 19.0% CSComs). Where women attend
for routine ANC only, the overriding reason why health workers
reported that IPTp-SP is not given is because women had not
eaten before attending ANC. As mentioned above there was a
perception amongst the majority of health workers interviewed
that SP causes dizziness and other mild symptoms when given to a
pregnant woman on an empty stomach. Health workers reported
two alternative courses of action where this was the case. The first
was to give the SP tablets to the woman to take at home, and the
second was to not give SP. Some health workers reported that the
pregnant women were asked to eat and return for the dose of
IPTp-SP. Where the tablets were given to take at home
instructions on how to take in relation to food were reported to
be given, and the adoption of special packaging to facilitate
understanding of how to take was undertaken by some. Where
women were not given tablets to take at home, examples of the
reasons for adopting this strategy based upon experience were
given and are presented in Table 1.
Based on the interviews with health workers, in most health
facilities pregnant women who attend ANC with an illness are
treated for the illness before performing routine ANC visits, this
may therefore influence whether a pregnant woman of eligible
gestation receives IPTp-SP on attendance at ANC. This is not the
case in all health facilities but responses may depend upon the
specific illness or disease, its severity, and the point at which during
the ANC visit it is reported or identified. Several health workers
reported illness as a factor promoting attendance for routine ANC
and having malaria treatment as a reason for not giving IPTp-SP.
Take SP by DOT
Where IPTp-SP is given, according to national guidelines it
should be given by DOT. Amongst pregnant women of eligible
gestation attending the CSRef 0% were given IPTp-SP by DOT
on their first visit to ANC and 2.1% on their second visit. Amongst
pregnant women attending CSComs for their first ANC and
second ANC visits 24.5% and 25.4% were given IPTp-SP by
DOT, respectively (Webster et al Unpublished).
The reasons for not giving by DOT were often the reasons that
IPTp-SP was not given at all and related to the dizziness when
taken by a woman who had not eaten. The categories of health
systems issues impacting upon delivery of IPTp-SP by DOT are
intricately linked to service delivery (Figure 2) and much less
diverse than those impacting upon whether a woman receives
IPTp-SP; they are therefore described together here.
Although there was acknowledgment of guidelines stating that
IPTp-SP should be given by DOT, reasons that these were not
practiced mostly related to side effects of IPTp-SP. It was reported
that the problem of side effects of SP for pregnant women when
taken on an empty stomach was included in training. During
training health workers were recommended that women should be
advised to eat before coming to ANC.
The giving of IPTp-SP was reported to be included in the
supervisory checklists. However, supervisory visits had discouraged
the use of DOT and recommended that women be given SP to
take at home. This had resulted in the shift from the
recommended national strategy in some facilities to one instigated
by the supervisors which was out of line with national policy.
The majority of health workers interviewed had decided,
through personal experience, reports of pregnant women, training,
or supervision that the side effects of SP were such that it should
not be taken by pregnant women who had not eaten recently.
Following from this, health workers have at least three options
which are to give the pregnant woman the tablets to take at home
(or elsewhere) after eating, to advise the woman to eat and return
for the dose by DOT, or not to give at all. Although the majority
of the reports from the health workers were on their own
perception of side effects of SP, the refusal to take IPTp-SP
without eating was sometimes at the instigation of the pregnant
women themselves.
None of the health workers interviewed said that they do not
give IPTp-SP to an eligible woman, rather they said that they do
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not give it by DOT due to side effects and they then discussed
reasons that they would not give it to be taken at home. These
reasons were all down to disbelief that the woman would take the
SP at all, or that she would take in incorrectly. Often these were
based on the health worker having observed the tablets at a later
date. Conversely, a report of side effects after taking was seen as
proof that it was taken.
‘‘As SP should be taken as DOT, you need to sensitize women that
water is here and that she must take it. We always ask if she has eaten
before we give the SP............If they go home with it [SP], there is no
certainty that they will take it.’’ (Health worker 7)
‘‘Some don’t take as it should be [IPTp-SP given to take at home].
Some throw it away because they don’t want to take drugs or some will
just keep it.’’ (Health worker 9)
‘‘Many even may refuse to take it if they know how to take it. Some do
not take for any reason. Some women throw it away because they don’t
like to take drugs. They also sometimes keep it somewhere. That is why
we ask them to take it here.’’ (Health worker 15)
‘‘If you give to take at home, they will not take it correctly, or they said
that they take it separately the tablets with interval between the tablets.’’
(Health worker 12)
Because some say that they had a malaise after they take it. So this is the
proof that they took it. (Health worker 6).
Where IPTp-SP is given as DOT the response was often that is
taken by DOT because they have water available. Reasons for
giving IPTp-SP by DOT were mainly the disbelief that the women
would take it otherwise.
‘‘Yes, they take it as a DOT because they think that the three tablets are
too much for them. So that is why we give them to take in here.’’ (Health
worker 8).
Offered ITN
There were a relatively limited range and number of reasons
given by health workers on why women may not receive an ITN
on their first visit to ANC (Figure 3). This may reflect, or be a
reason for the higher proportion of eligible pregnant women
receiving ITNs where they were in stock (81.7%; ITNs were
stocked-out in the CSRef and in 2 CSComs) in comparison to
those eligible receiving a dose of IPTp-SP (63.9% in the CSRef
and 74.0% in the CSComs) or IPTp-SP by DOT (0% in the
CSRef and 34.3% in the CSComs) in the quantitative study
Webster et al Unpublished. Reasons given from the perception of
health workers interviewed related to the supply of ITNs mainly
on the transportation and cost of transportation; and to service
delivery.
The number of ITNs to be supplied to the regions, districts and
CSComs are based upon estimates of the catchment population at
each level. This has implications for the availability of ITNs at the
CSComs as discussed below, but the main problem reported by
health workers in assuring a supply of ITNs for delivery to
pregnant women was that of transport, and the cost of transport.
‘‘This scheme of provision [of ITNs] start from the central level to the
DRS (regional level) is the regional level to the district, and to the
CSCOM............ At each level there is a threshold and you do the order
each time that threshold is reached. You don’t wait until the ITNs finish
to order. At central level there is scheme that provides items.’’ (Health
worker 4)
The perception of health workers was that much of this problem
had been resolved by the support of Population Services
International (PSI) who began to transport ITNs to the CSCom
level.
‘‘PSI-MALI is responsible for this distribution from the national level
to the CSCom level. So there is no stock out. ‘‘ (Health worker 4)
‘‘We have PSI who supports to ensure the transport of inputs up to
CSCOM level. At that time, there is no problem.............with the
support from PSI the problem starts to be resolved.’’ (Health worker 10)
There was one clear reason identified during the interviews for a
pregnant woman on her first visit to ANC not being given an ITN,
this was where a woman was from a community outside of the
catchment area of the CSCom. Attendance at health facilities by
those from outside the official catchment area of the health facility
is common in Mali, such that the Health Management Informa-
tion System (HMIS) referred to as the DESAM captures
information for most indicators stratified by catchment and non-
catchment population.
Three further issues discussed that may have contributed to the
loss of effectiveness of delivery of ITNs, but which are dependent
upon interpretation. These reasons included that the health
worker would prefer to give on a second or third visit; that they felt
that ITNs should be given after delivery rather than before, and
that they don’t give to a woman in her second pregnancy because
she should have already received two ITNs, one in her first
pregnancy, and the other for her child from the Expanded
Programme of Immunisation (EPI) clinic. These factors all linked
to the widely held perception that pregnant women attended ANC
to get an ITN and then did not come again unless they were ill as
reported above.
‘‘Women don’t come as we hope because they come for ITNs. If we offer
them ITNs they just disappear.......... Usually they come at ANC visit
because of ITNs........’’. (Health worker 8)
‘‘Some women already have mosquito nets, but they are not treated. We
give them, but with stock out of ITN we ask them to come during the
second visit to receive their ITN. This has been changed because we give
now to all women who come for the first time. There are women who try
to benefit to ITNs; because they do antenatal visit in Bamako where
they receive ITNs, and come here for another first visit to receive a
second ITN.’’ (Health worker 6)
‘‘They frequent other CSCOMs, if ITN are available in Famori
(CSREF), they go there by paying the visit fees and get ITNs and they
never come back here. That is why the coverage is higher [ANC
coverage] for the first visit than the third visit.’’ (Health worker 7)
‘‘If women receive ITN during the first visit, she will never come for
subsequent visits. There was a problem of coordination. Some people
think that it is good to give ITN after delivery. Some also say to wait
until the third visit. Otherwise they will never come for subsequent visits
once they get it during the first visit.’’ (Health worker 7)
‘‘Those with two pregnancies must have [ITN] during their first
pregnancy or during vaccination of their baby nine months after
delivery................ They come to ANV more for ITNs.’’ (Health
worker 15).
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Discussion
This qualitative study has provided rich information on the
health systems context and the delivery of IPTp-SP and ITNs
within this context. Health workers discussed both their percep-
tions of implementation of these interventions within ANC and
reported directly upon their practices. The findings explain
reasons for ineffective implementation of the interventions; some
of these reasons are directly related to the interventions, and others
are due to the broader health systems context. The knowledge,
understandings, perceptions and practices of the health workers
involved are central to the health system and how it functions [13].
There are some potential limitations to this study, the first of
which is that only 18 health workers were interviewed. These
health workers represented a variety of cadres involved in either
guidance for or direct delivery of ANC. Due to low numbers of
individuals at some of these levels, there being no noteworthy
differences between the perspectives of the cadres interviewed, and
in order to maintain anonymity, we do not report the findings
linked to level or cadre of health worker. However, the interviews
undertaken produced rich information with the majority of
interviewees presenting the same discussions and therefore
saturation of emergent themes was reached. The coding and
analysis were conducted by only one investigator but the
production of the Mindmaps provided a point for confirmation
of the major themes by other investigators who had conducted,
transcribed and translated the interviews, and who were involved
during implementation of the interviews with the inductive
revision of themes on a daily basis. These therefore contributed
to the reflexivity of the study [14].
There are several factors directly impacting upon the effective-
ness of pregnant women receiving IPTp-SP at ANC, the first of
which is misunderstanding of the policy for when the doses should
be given. This misunderstanding is a link between complicated
policy guidelines, poor implementation of this policy (training,
information communication and leadership) and poor implemen-
tation of the intervention. There is a large literature on the impact
of guidelines on implementation and factors influencing the
implementability of guidelines [15,16,17], including reports from
other settings with IPTp-SP [18]. The policy of ‘give between the
4th and 8th months of pregnancy’ was interpreted by many health
workers as that IPTp-SP should not be given in the eighth month.
This provided a plausible explanation as to why being of 4 to
6 months gestation in comparison to 7 to 8 months gestation was a
quantitative predictor of receiving IPTp-SP during an ANC visit
(Webster et al Unpublished). It is possible therefore to draw a
direct link between health workers reporting that they don’t give
IPTp-SP in the 8th and sometimes 7th month of gestation and a
reduction in the proportion of eligible women receiving this
intervention.
The policy guidance that IPTp-SP should not be given during
the 9th month of pregnancy was probably due to safety concerns
on the possibility of kernicterus in the neonate. However, IPTp-SP
is now considered to have a favourable safety profile in the second
and third trimesters [19]. Reduced protection due to pregnant
women not receiving IPTp-SP late in the 3rd trimester has been
shown in Mali [10]. This was not the policy recommended by
WHO but was introduced at the country level. Mali has recently
dropped this recommendation in new policy guidelines [20].
The second factor influencing whether an eligible woman is
given IPTp-SP is also a reason why they are not always given this
intervention by DOT. This relates to side effects of IPTp-SP when
taken on an empty stomach and the way in which this has been
interpreted by health workers, with its cause and effect involving
several building blocks of the health system. It was the perception
of the majority of health workers interviewed that giving a
pregnant woman IPTp-SP when she had not eaten would cause
side effects. These side effects included dizziness, nausea, and
fatigue most commonly. Some of these side effects were reported
as experienced in their clients by the health workers. For others,
the reason was that they also reported having been taught this
during their training. During training some health workers had
been taught that it is preferable because of the side effects (and
particularly if the woman had not eaten), not to give IPTp-SP by
DOT, but rather to give the pregnant woman the tablets to take at
home, with instructions that they should be taken with food.
Similar messages were also reported from supervision visits. This
represents an agreement by the trainers that IPTp-SP should not
be given on an empty stomach and a positive indication to health
workers that they should not give IPTp-SP to a woman who has
not eaten recently. It also provides an explanation why women of
eligible gestation may not be given a dose of IPTp-SP when
accessing ANC, that is, if they have not eaten before the visit. In
order to get a dose of IPTp-SP they would then need to eat and
return. This situation represents institutionalisation of a message
which seriously undermines the national policy.
Where adverse events due to SP have been assessed in trials
these have been seen in a high proportion of women 48% and
41% in Ghana [21,22]. The side effects have included general
body weakness, dizziness, vomiting, nausea, abdominal pain,
diarrhoea, body itch, and body rash. However, these side effects
are transient and should be managed in the ANC. Guidance on
how to deal with any side effects brought about by implementing
the policy should be given during training and supervision rather
than advice which clearly contravenes one of the elements of the
guidance, which is DOT. The IPTp-SP guidelines in Kenya for
example, were updated to include the statement ‘can be given on
an empty stomach’ to circumvent these problems. Without
guidance, the frontline health workers had developed a number
of ways of dealing with this problem, none of which were as
effective in protecting pregnant women as the national policy
guidance. Besides the policy guidance on what should be given,
these studies have shown the need for guidance on how to give
interventions. These may be termed strategy guidance, supporting,
or ‘soft’ policies, but it is clear that lack of such guidance can have
a profound impact on the effectiveness of implementation of
interventions.
Whilst many women attend ANC whilst they are ill, there was
no consistency in the reported processes through which a pregnant
woman progresses if she attends ANC with symptoms of malaria
or other illnesses. Some health workers reported that the illness
would be dealt with first and others that routine ANC would come
first and the illness would be dealt with subsequently. The range in
responses may have been due to the lack of specificity of the
question where respondents were thinking about different illnesses,
but mostly these discussions were in the context of malaria. It is
likely that the point at which the illness is reported, discussed or
discovered during the visit may have an influence the process and
therefore content of management. This may have been an
explanation of the quantitative finding that being palpated was a
positive predictor of receiving IPTp-SP in ANC, as an indicator of
the woman having progressed through ANC to reach an
examination in consultation. More research is needed in this area
as it is possible that women who should receive IPTp-SP are not
receiving it because of the way in which they progress through
ANC and are diverted to deal with an illness. In Mozambique,
whilst 77% of pregnant women presented in a hospital based study
with symptoms of malaria, only a small proportion of them (27%)
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were found to be parasitaemic [23]. In a setting without
diagnostic/parasitic confirmation of malaria, this would result in
a large proportion of women who would should not receive
treatment being treated inappropriately, and would prevent these
women from being given IPTp-SP. There is relatively little
information in the literature on the case management of malaria in
pregnancy outside of trial settings, and we are not aware of any
literature on the interplay between malaria prevention and
treatment in an operational setting. The findings of this study
suggest that this subject deserves more attention and more
guidance needs to be given to frontline health workers on how
to manage parasitaemic pregnant women attending ANC for a
dose of IPTp-SP. Again strategy guidance would be key to solving
ineffective implementation.
The only tangible explanation from the qualitative study as to
why pregnant women would not receive an ITN on their first visit
to ANC, where they were in-stock, was that of rationing to women
from the defined catchment area. Other rationing decisions were
made by individual health workers, such as reserving for later visits
so that the woman would return, were not frequently mentioned.
This supports the findings of the quantitative study that where
stock of ITNs can be maintained, delivery will be effective.
Each of the issues discussed above are ones that relate directly to
the specific intervention and can potentially be solved in the short
term and by resolving issues in strengthened policy and strategy
guidance, and communication of and training in this guidance.
Whilst we recognise that having good strategy guideline
documentation alone is insufficient to ensure high-quality perfor-
mance of health workers [24], it is certainly a pre-requisite.
Governance, supervision, and human resource issues in terms of
training also need to be addressed to assure success. However,
together these are relatively simple as compared with issues of
financing and product and supply chain management, which both
link to embedded health system problems.
Pregnant women accessing ANC were charged fees for services
and medicines, often even when policy stated they were to be given
free. The fees also varied between health facilities. Stock-outs of SP
and ITNs linked to financing problems often due to the lack of fuel
to transport supplies to the peripheral health facilities. Many of the
predictors of receiving the interventions linked to fees, particularly
for ITNs. The community based financing system in Mali requires
the generation of finances at the health facility level to support
staffing, medicines and their transport. Although prioritisation and
striving for efficiency may help to some extent it is difficult to
identify strategies in the immediate term to solve the financing
problems. It is more important to ensure the maximum
effectiveness and efficiency in the delivery of the interventions
within this health system context.
Categorising reasons for loss of effectiveness across building
blocks of the health system helped to gain a clear picture of not
only what needs to be addressed, but also how. However, the
majority of issues raised could be classified under at least two and
more often more of the health systems building blocks. The
concept that the health systems building blocks are not exclusive
and that there are many overlaps has been well developed and
discussed [12,13]. Where this is the cases we have not necessarily
presented all of these possible links, but have focussed on the block
for which there is a stronger link, or for which there is a clear
actionable intervention in the shorter term.
We used two methods to attempt to explain the reasons that 3
intermediate processes were ineffective as identified in the
quantitative study. These methods were quantitative predictors
of the effectiveness of the processes in the companion paper
(Webster et al Unpublished) and qualitative analysis of in-depth
interviews with health workers presented in this paper. Combining
the findings from these two studies we found quantitative
predictors that were explained by qualitative findings, and others
for which the qualitative study provided no further explanatory
information (Table 2). In addition, there were important findings
from the qualitative study that were missed by the quantitative
predictors. The quantitative predictors of receiving any IPTp-SP
by women of eligible gestation during ANC that were explained by
the qualitative study were those relating to diagnostic categories of
governance: guidelines, governance: co-ordination and harmoni-
sation, financing: subsidy and service delivery: illness. Quantitative
predictors of receiving`IPTp-SP by DOT or of being offered an
ITN were not explained by the qualitative findings with the
exception of those relating to financing. Triangulation with the
findings of the companion quantitative study strengthens the
interpretation of the qualitative findings. As there was an
18 months gap between the quantitative and qualitative studies
we do not suggest that the findings are directly linked in time.
However, as the majority of issues raised in the qualitative study
are not of a transient nature but rather are well ingrained within
the structure of the facility and broader health system and within
the behaviours of health workers, this time gap does not
undermine the use of the qualitative study to explain the findings
of the quantitative study.
Conclusions
Despite broad health systems issues being highlighted across all
health systems building blocks, issues actionable in the short-term,
specific to IPTp-SP and ITNs dominated. Ineffective delivery of
IPTp-SP was due to misunderstanding of the upper limit of the
gestational age at which it could be given, the required interval
between doses and to concerns on the side effects of giving IPTp-
SP to pregnant women on an empty stomach. It is likely that these
factors alone account for the majority of the substantial loss in
effectiveness measured in the companion quantitative study. New
policy and strategy guidelines should be simplified, developed and
disseminated. Other losses in effectiveness are likely due to the
process of ANC for women who present with an illness. More
research is required to elucidate the interaction between treatment
and prevention of malaria in pregnancy at ANC.
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